Schematic representation of the movement of the flower?like particle as it makes its way through a cellular trap to deliver therapeutic genes.
Washington State University researchers have developed a novel way to deliver drugs and therapies into cells at the nanoscale without causing toxic effects that have stymied other such efforts.
The work could someday lead to more effective therapies and diagnostics for cancer and other illnesses.
Led by Yuehe Lin, professor in WSU’s School of Mechanical and Materials Engineering, and Chunlong Chen, senior scientist at the Department of Energy’s Pacific Northwest National Laboratory (PNNL), the research team developed biologically inspired materials at the nanoscale that were able to effectively deliver model therapeutic genes into tumor cells. They published their results in the journal, Small.
Researchers have been working to develop nanomaterials that can effectively carry therapeutic genes directly into the cells for the treatment of diseases such as cancer. The key issues for gene delivery using nanomaterials are their low delivery efficiency of medicine and potential toxicity.
“To develop nanotechnology for medical purposes, the first thing to consider is toxicity — That is the first concern for doctors,” said Lin.
The flower?like particle the WSU and PNNL team developed is about 150 nanometers in size, or about one thousand times smaller than the width of a piece of paper. It is made of sheets of peptoids, which are similar to natural peptides that make up proteins. The peptoids make for a good drug delivery particle because they’re fairly easy to synthesize and, because they’re similar to natural biological materials, work well in biological systems.
The researchers added fluorescent probes in their peptoid nanoflowers, so they could trace them as they made their way through cells, and they added the element fluorine, which helped the nanoflowers more easily escape from tricky cellular traps that often impede drug delivery.
The flower?like particles loaded with therapeutic genes were able to make their way smoothly out of the predicted cellular trap, enter the heart of the cell, and release their drug there.
“The nanoflowers successfully and rapidly escaped (the cell trap) and exhibited minimal cytotoxicity,” said Lin.
After their initial testing with model drug molecules, the researchers hope to conduct further studies using real medicines.
“This paves a new way for us to develop nanocargoes that can efficiently deliver drug molecules into the cell and offers new opportunities for targeted gene therapies,” he said.
The WSU and PNNL team have filed a patent application for the new technology, and they are seeking industrial partners for further development.
Learn more: Bioinspired nanoscale drug delivery method developed by WSU, PNNL researchers
The Latest on: Nanoscale drug delivery
via Google News
The Latest on: Nanoscale drug delivery
- Biomaterials and Tissue Engineeringon June 17, 2022 at 4:51 am
Nanoscale structure-property relationships of biological materials, genetic and molecular origins of soft joint tissue diseases, biomaterials under extreme conditions, coupling between ...
- Nanomedicine Market Size Worth USD 393.04 Billion By 2030 At 9.2% CAGR - Report By Market Research Future (MRFR)on June 17, 2022 at 12:02 am
or the development of medicinal technology involving nanoscale modifications, has expanded quickly. Significant improvements have been made in targeted medication delivery, controlled drug release ...
- Nanomedicine Strategies for Hematological Malignancies: What Is Next?on June 16, 2022 at 5:00 pm
The potential for a cancer patient to be treated and monitored in real-time with a combined nanoscale drug-delivery and imaging system could turn the dream of Nobel Prize winner Richard Feynman ...
- Plus Therapeutics Completes Enrollment Of Cohort 1 Respect-LM Phase 1/2A Trialon June 16, 2022 at 6:13 am
The investigational drug, 186RNL, is a proprietary nanoscale compound with a unique ... platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal ...
- Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trialon June 16, 2022 at 5:51 am
CloseCurlyDoubleQuote; The investigational drug, 186RNL, is a proprietary nanoscale compound with a unique chelated ... nanotechnology platform is currently centered around the enhanced delivery of a ...
- Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trialon June 16, 2022 at 4:30 am
Targeted Radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort Next step: Data Safety & Monitoring Board to consider further dose escalation AUSTIN, Texas, June 16 ...
- Upgraded Nanoscale Drills Kill Bacteria Directly and Revive Existing Antibioticson June 2, 2022 at 5:06 am
The latest iteration of these synthetic nanoscale drills ... while MMs have shown promise for applications ranging from drug delivery to chemo- or antimicrobial therapy, the ultraviolet (UV ...
- Nanopharmaceutical Drugs Market Size And Forecast | Amgen Inc., AstraZeneca PLC, Gilead Sciences Inc., Novartis AG, Johnson & Johnsonon May 30, 2022 at 3:57 am
Existing pharmaceuticals formulation into the nanoscale has resulted in lower toxicity levels and better cell specificity. A major concern linked with conventional drug delivery systems is the ...
- Strategies for Improving Mucosal Drug Deliveryon May 24, 2022 at 4:59 pm
Gastrointestinal mucus generally exists as two layers, a basal 'unstirred' or 'firmly adherent' layer and a luminal 'stirred' or 'sloppy' layer [74–76] ; however, most of the cited references ...
via Bing News